Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted)

doi:10.1182/blood-2010-06-288837

Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

Cart

Sign In

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

Continuing Medical Education (CME) questions| June 24, 2010

Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted)

CME

Blood (2010) 115 (25): 5280–5281.

https://doi.org/10.1182/blood-2010-06-288837

Split-Screen
Share
- Facebook
- Twitter
- LinkedIn
- Email
Tools
- Request Permissions
- Cite
Search Site
Open the PDF for in another window

Citation

Continuing Medical Education (CME) questions: Treatment of acute promyelocytic leukemia based on 2 regimens (LPA99- ATRA + idarubicin -AIDA and LPA2005-risk adjusted). Blood 2010; 115 (25): 5280–5281. doi: https://doi.org/10.1182/blood-2010-06-288837

Download citation file:

Ris (Zotero)
Reference Manager
EasyBib
Bookends
Mendeley
Papers
EndNote
RefWorks
BibTex

toolbar search

search input Search input auto suggest

filter your search

Search

Topics:

acute promyelocytic leukemia, education, medical, continuing, idarubicin, tretinoin

This content is only available as a PDF.

2010

Article PDF first page preview

Sign in via your Institution

Submit a comment

Name Please enter your name.

Affiliations Please enter your affiliations

Comment title Please supply a title for your comment.

Comment This field is required

I agree to the terms and conditions. You must accept the terms and conditions.

Read the terms and conditions

You have entered an invalid code.

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Comment not saved. Please try again.

This feature is available to Subscribers Only

Sign In or Create an Account

My Account

Sign In

Volume 115, Issue 25

June 24 2010

Previous Article

Advertisement intended for health care professionals

Sign in via your Institution

View Metrics

×

Cited By

Google Scholar

Email alerts

Article Activity Alert

First Edition Alert

Latest Issue Alert

Advertisement intended for health care professionals

Current Issue
First edition
All Issues

Collections
Abstracts
Authors

Submit to Blood
About Blood
Subscriptions

Public Access
Permissions
Alerts

Contact Us
Newsroom
Blood Classifieds

Advertising in Blood
Terms and Conditions
Twitter

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Neoplasia
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals